Need a specific person's email?
Browse TME Pharma's employee directory (about 12 employees) and reveal verified emails free.
TME Pharma's most common email format is FLast@noxxon.com (ex. JDoe@noxxon.com), used for 86% of noxxon.com addresses. TME Pharma uses 7 email patterns across 2 domains: noxxon.com and tmepharma.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of noxxon.com |
|---|---|---|
| FLast@noxxon.comMost common | JDoe@noxxon.com | |
| First.L@noxxon.com | John.D@noxxon.com | |
| LastFi@noxxon.com | DoeJo@noxxon.com | |
| LFirst@noxxon.com | DJohn@noxxon.com |
| Format | Example | Share of tmepharma.com |
|---|---|---|
| FLast@tmepharma.comMost common | JDoe@tmepharma.com | |
| FMiddleLast@tmepharma.com | JMichaelDoe@tmepharma.com | |
| FMLast@tmepharma.com | JMDoe@tmepharma.com |
Browse TME Pharma's employee directory (about 12 employees) and reveal verified emails free.
Pharmaceutical ManufacturingBerlin, Germany11-50 Employees
TME Pharma is a clinical-stage pharmaceutical company focused on developing therapies for aggressive cancers by targeting the tumor microenvironment. The company is based in Berlin, Germany, and employs 11-50 people. Its lead candidate NOX-A12 is described as acting through two mechanisms of action and is being developed for glioblastoma, with topline clinical results reported. NOX-A12 is characterized as a CXCL12 inhibitor within its mechanism. Regulatory updates in 2025 included the FDA Fast Track designation for NOX-A12 in combination with radiotherapy and bevacizumab for glioblastoma and the approval by the FDA and German BfArM of the design of a randomized Phase 2 trial in glioblastoma.
Most common format
FLast@noxxon.com
Example: JDoe@noxxon.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.